Sergio Traversa has bought RLMD on 8 days since Dec 2022

Sergio Traversa (age 64) is the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage biotechnology company, a position he has held since April 2012.( Under his leadership, Relmada executed a strategic pivot in 2024–2025, pausing programs like REL-1017 and REL-P11 following Phase 3 data, and in-licensing NDV-01 for NMIBC from Trigone and acquiring sepranolone from Asarina to focus on nearer-term value drivers, with key milestones including NDV-01 Phase 2 data at AUA 2025.(

Traversa brings over 25 years of experience in healthcare across pharmaceuticals, investing, and advisory roles in the US and Europe.( His career highlights include co-founding and serving as CEO of Medeor Inc. (2010–2012), a Cornell University spinoff; founding partner at Ardana Capital (2008–2010); Area Manager for Southern Europe at Therakos (Johnson & Johnson); and Marketing Manager in Eli Lilly's Hospital Business Unit and CNS team, contributing to Prozac launch and early Zyprexa/Cymbalta development.( He holds a Laurea in Pharmacy from the University of Turin and an MBA in Finance/International Business from NYU Stern.(

Written by Perplexity from public sources.